

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
7126-2APPLICATION NO.  
09/913,401

Rev P2 (88)

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

DEC 17 2001

(Use several sheets if necessary)

APPLICANT

Pollak, Alfred, et al.

FILING DATE

08/10/01

GROUP

1641-1616

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE
RG	A1	5,789,555	August 4, 1998	Pollak Alfred	—	—
RG	A2	5,659,041	August 19, 1997	Dunn-Dufault, Robert, et al.	—	—

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
RG	B1	WO 96 037427 A	8 Feb. 1996	WO			
RG	B2	WO 93 17719 A	16 Sept. 1993	WO			
RG	B3	WO 99 40947 A	19 Aug. 1999	WO			

## OTHER DOCUMENTS

RG	C1	Smith, C.J. et al. "Evaluation of a Novel N3S Chelation System for the Preparation of Tc-99m and Re-188 Labeled Biomolecules." <i>J. Nuclear Med.</i> (May 1998) Vol. 39, No.5 Suppl.:215 : 45th Annual Meeting of the Society of Nuclear Medicine, Toronto, Ontario, Canada June 7-11, 1998 Society of Nuclear Medicine.
RG	C2	Wong, Ernest et al. "Synthesis and Structural Characterization of Tc-99m and Re oxo Complexes with N <sub>1</sub> -N <sub>2</sub> S <sub>1</sub> Peptidic Ligands." <i>J. Nuclear Med.</i> , (1997) Vol. 38, No. 5 Suppl.:148: 44th Annual Meeting of the Society of Nuclear Medicine, San Antonio, Texas, USA, June 1-5, 1997.
RG	C3	Pollak, A., et al., "Inflammation with Novel Peptidic Technetium-99m Chelators Linked to a Chemotactic Peptide", <i>J. Nuclear Med.</i> , Vol. 35 (5) Suppl. June 1994, 44P-45P, Proceedings of the 41st Annual Meeting, New York City, NY.
RG	C4	Knight, L.C., "Thrombus Imaging with Technetium-99m Synthetic Peptides Based upon the Binding of a Monoclonal Antibody to Activated Platelets", <i>J. Nuclear Med.</i> Vol. 95 (2) February 1994, 282-288.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP §09; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY